Largest biotech by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
CG Oncology has the lowest figure of the 24 biotech ranked by total liabilities, at ZAR 672.2M, followed by Immunovant (ZAR 1.8B) and Krystal Biotech (ZAR 2B). Figures as of 18 Nov 2026, 16:02 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- Lowest
- CG OncologyZAR 672.2M
- Median
- ZAR 12.1B
- Combined market value
- ZAR 14.5T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | CG OncologyCGON · Health Care | ZAR 672.2M | ZAR 123.3B | ZAR 1,379.96 | 1.39% up | 85% up | ||
| 2 | ImmunovantIMVT · Health Care | ZAR 1.8B | ZAR 120.3B | ZAR 581.36 | 1.54% up | 43% up | ||
| 3 | Krystal BiotechKRYS · Health Care | ZAR 2B | ZAR 157.7B | ZAR 5,320.69 | 3.37% up | 46% up | ||
| 4 | Scholar Rock HoldingSRRK · Health Care | ZAR 2.7B | ZAR 99.6B | ZAR 816.27 | 5.02% up | 14% up | ||
| 5 | Kymera TherapeuticsKYMR · Health Care | ZAR 2.8B | ZAR 177.4B | ZAR 2,077.86 | 0.82% down | 87% up | ||
| 6 | Twist BioscienceTWST · Health Care | ZAR 2.9B | ZAR 135.1B | ZAR 1,981.06 | 2.59% up | 340% up | ||
| 7 | Kodiak SciencesKOD · Health Care | ZAR 3.3B | ZAR 109.8B | ZAR 1,679.08 | 0.61% up | 396% up | ||
| 8 | Adaptive BiotechnologiesADPT · Health Care | ZAR 5B | ZAR 79.7B | ZAR 492.27 | 0.22% up | 88% up | ||
| 9 | VaxcytePCVX · Health Care | ZAR 5.5B | ZAR 159.5B | ZAR 1,007.55 | 1.62% down | 22% up | ||
| 10 | CRISPR TherapeuticsCRSP · Health Care | ZAR 5.9B | ZAR 69.2B | ZAR 713.68 | 3.10% up | 21% down | ||
| 11 | Bio-TechneTECH · Health Care | ZAR 8.2B | ZAR 197B | ZAR 1,254.01 | 0.14% up | 26% up | ||
| 12 | ExelixisEXEL · Health Care | ZAR 11.8B | ZAR 289.7B | ZAR 1,187.38 | 0.54% up | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | ZAR 12.5B | ZAR 596.5B | ZAR 2,758.02 | 1.67% down | 131% up | ||
| 14 | RepligenRGEN · Health Care | ZAR 14.5B | ZAR 189.5B | ZAR 2,963.96 | 6.00% up | 5% up | ||
| 15 | ImmunityBioIBRX · Health Care | ZAR 17.3B | ZAR 120.9B | ZAR 113.62 | 5.27% up | 193% up | ||
| 16 | argenxARGX · Health Care | ZAR 23.4B | ZAR 1.03T | ZAR 16,348.62 | 0.08% up | 4% up | ||
| 17 | Neurocrine BiosciencesNBIX · Health Care | ZAR 23.8B | ZAR 284.9B | ZAR 2,814.57 | 1.61% down | 20% up | ||
| 18 | Halozyme TherapeuticsHALO · Health Care | ZAR 42.7B | ZAR 191.6B | ZAR 1,680.64 | 1.57% up | 37% up | ||
| 19 | QiagenQGEN · Health Care | ZAR 43.2B | ZAR 176.6B | ZAR 855.06 | 0.31% down | 12% up | ||
| 20 | BioNTechBNTX · Health Care | ZAR 52.9B | ZAR 359.3B | ZAR 1,449.26 | 0.94% down | 16% down | ||
| 21 | ModernaMRNA · Health Care | ZAR 63.6B | ZAR 1.41T | ZAR 3,479.20 | 2.42% down | 755% up | ||
| 22 | BiogenBIIB · Health Care | ZAR 192.8B | ZAR 637.1B | ZAR 4,310.21 | 0.32% down | 49% up | ||
| 23 | Gilead SciencesGILD · Health Care | ZAR 627.6B | ZAR 3.61T | ZAR 2,910.42 | 0.85% down | 33% up | ||
| 24 | AmgenAMGN · Health Care | ZAR 1.41T | ZAR 4.18T | ZAR 7,724.24 | 2.16% down | 34% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 17.2408 ZAR).
Questions and answers
Which biotech have the lowest total liabilities?
CG Oncology (ZAR 672.2M), Immunovant (ZAR 1.8B) and Krystal Biotech (ZAR 2B) have the lowest total liabilities of the 24 biotech ranked here as of 18 Nov 2026, 16:02 UTC.
How many biotech are in this ranking?
24 are ranked by total liabilities.
What are these biotech worth together?
The 24 biotech ranked by total liabilities have a combined market value of ZAR 14.5T as of 18 Nov 2026, 16:02 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.